Evicenter
Vyndamax (tafamidis) in Transthyretin amyloid cardiomyopathy
Manufacturer
Pfizer Inc
Questions
71
Last updated

All questions

Guidelines: Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy

1 question · 1 source

Guidelines

Is Vyndamax recommended in ATTR-CM treatment guidelines?

Note: Both statements are the manufacturer's summaries on the Vyndamax HCP efficacy page; the guideline texts, including the population and level of evidence of each recommendation, were not captured. The 2022 document is a heart failure guideline, and the 2025 document is an ACC concise clinical guidance on transthyretin cardiac amyloidosis.